HealthDay News — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without ...

This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

Are compounded GLP-1s safe? Dr Ro breaks down the risks, FDA concerns, and telemedicine's role in prescribing these meds — what physicians must know to protect their patients.

More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.